Veracyte Stock Price, News & Analysis

Veracyte (VCYT) presented new data at the 2025 ASCO Genitourinary Cancers Symposium demonstrating the effectiveness of its Decipher Prostate and Bladder tests in guiding cancer treatment. Key findings from 17 Decipher-focused abstracts showed that the Decipher Prostate Genomic Classifier can help identify patients who will benefit from pelvic nodal radiation therapy, while the Decipher Bladder test accurately identified less aggressive cancer cases based on molecular subtypes.

Additionally, research using Veracyte's Decipher GRID tool validated the PORTOS signature's ability to predict patient response to different radiation therapy dosages. The study, also published in Annals of Oncology, analyzed data from two Phase 3 trials, showing that patients with higher PORTOS scores significantly benefited from increased radiation doses in both salvage and definitive radiotherapy settings.

Veracyte (VCYT) announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium, demonstrating the effectiveness of its Decipher tests in guiding treatment decisions for prostate and bladder cancers. Key findings include the Decipher Prostate test's ability to inform treatment intensification strategies in salvage radiotherapy patients, and the Decipher Bladder test's accuracy in identifying favorable outcomes in bladder cancer patients.

The research presentations highlight the test's market leadership and inclusion in NCCN guidelines. Notable studies include validation of the PORTOS gene expression signature for predicting radiation therapy response, and a large-scale analysis showing Decipher Prostate's robust prognostic performance. The symposium will take place February 13-15 in San Francisco.

Veracyte (VCYT) announced new data supporting its Decipher Bladder Genomic Subtyping Classifier's effectiveness in improving bladder cancer staging. The study, published in European Urology Open Science, analyzed 226 patients from eight medical centers who underwent radical cystectomy without neoadjuvant chemotherapy.

Key findings showed that 33% of patients experienced pathological upstaging to non-organ-confined disease (19% for NMIBC and 53% for T2 disease). The study revealed that NMIBC patients with non-luminal tumors were more likely to be upstaged to MIBC compared to those with luminal tumors (51% vs. 32%). Additionally, patients with luminal-subtype bladder cancer demonstrated better overall survival based on a 33-month median follow-up.

This research adds to Veracyte's growing clinical evidence supporting its molecular tests in urology, where its Decipher Prostate Genomic Classifier is already the market leader.

Veracyte (VCYT), a leading cancer diagnostics company, has announced it will release its Q4 and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The event will be accessible through a live webcast from the company's website, with dial-in registration available for the conference call. A webcast replay will be made available on the company's investor relations website following the broadcast.

Veracyte's Decipher Prostate Genomic Classifier has achieved a significant milestone as the only gene expression test included in the 2025 NCCN Clinical Practice Guidelines for prostate cancer. The test, which uses a 22-gene signature to assess the likelihood of prostate tumor metastasis, helps clinicians make informed treatment decisions.

The test's inclusion in the guidelines is backed by extensive validation through numerous peer-reviewed studies and analyses from multiple Phase 3 clinical trials. As the most widely used molecular test in prostate cancer, this recognition in the NCCN guidelines is expected to increase its accessibility to more patients.

Veracyte reported its third quarter 2024 financial results, showing a 29% increase in total revenue to $115.9 million and a 34% rise in testing revenue to $109.5 million. The company achieved a net income of $15.2 million, a 151% improvement year-over-year, with adjusted EBITDA growing by 117% to $27.3 million. Testing volume increased by 24% to 36,792 tests, driven by strong performance in Decipher and Afirma tests. Decipher revenue grew by 48%, while Afirma revenue increased by 19%. Product revenue and biopharmaceutical revenue saw declines of 21% and 23%, respectively. Veracyte raised its full-year 2024 revenue guidance to $442-$445 million, representing 22%-23% growth. The company expects year-end cash and equivalents to be between $280-$285 million.

Veracyte (VCYT) has announced its participation in four major investor conferences in November. The cancer diagnostics company will conduct fireside chats at the UBS Healthcare Conference (November 12th, 2:45 PM ET), Guggenheim Inaugural Healthcare Innovation Conference (November 13th, 3:00 PM ET), Wolfe Research Healthcare Conference (November 19th, 1:40 PM ET), and Stephens Annual Investor Conference (November 20th, 4:00 PM ET). Live audio webcasts will be available on Veracyte's investor website, with replays accessible for 90 days after each presentation.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the release date for its third quarter 2024 financial results. The company will disclose these results after the market closes on Wednesday, November 6, 2024.

Following the release, Veracyte's management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will provide a general business update and discuss the financial results. Investors and interested parties can access the live webcast through the company's website or via the provided link: https://edge.media-server.com/mmc/p/kzh3s376.

For those unable to attend the live event, a webcast replay will be made available on Veracyte's investor relations website. Conference call dial-in information can be obtained by registering at the provided link.

Veracyte, Inc. (Nasdaq: VCYT) announced new data from the VANDAAM trial showing that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men with early-stage disease. The findings were presented at ASTRO 2024 in Washington, D.C.

Key points:

• African American men are 70% more likely to be diagnosed with prostate cancer and twice as likely to die from it compared to white men.
• The study included 226 men (113 African American and 113 non-African American) with low- or intermediate-risk prostate cancer.
• Patients with high Decipher test scores were eight times more likely to have biochemical recurrence within 2 years.
• Results showed no significant difference between African American and non-African American men.

This study is the first prospective clinical trial examining genomic risk-stratification in African American men, potentially helping to narrow the prostate cancer disparity gap.